Clinical Assessment of Anti-Viral CD8+ T Cell Immune Monitoring Using QuantiFERON-CMV® Assay to Identify High Risk Allogeneic Hematopoietic Stem Cell Transplant Patients with CMV Infection Complications

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Tey, Siok Keen ^a,b,c   Kennedy, Glen A ^b,c   Cromer, Deborah ^d   Davenport, Miles P ^d   Walker, Susan ^a   Jones, Linda I ^a   Crough, Tania ^a   Durrant, Simon T ^b   Morton, James A ^b   Butler, Jason P ^b   Misra, Ashish K ^b   Hill, Geoffrey R ^a,b   Khanna, Rajiv ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; FOSCARNET; GANCICLOVIR; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; VALACICLOVIR; VALGANCICLOVIR;

ACUTE LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DIAGNOSTIC KIT; DIAGNOSTIC TEST; DISEASE SEVERITY; FEMALE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEMOPHAGOCYTIC SYNDROME; HIGH RISK PATIENT; HUMAN; HUMAN CELL; IMMUNOLOGICAL MONITORING; INCIDENCE; MALE; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; NONHODGKIN LYMPHOMA; NONHUMAN; OBSERVATIONAL STUDY; PROGNOSIS; PROSPECTIVE STUDY; VIREMIA; VIRUS IMMUNITY; VIRUS LOAD; VIRUS REACTIVATION;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; BIOLOGICAL ASSAY; CD8-POSITIVE T-LYMPHOCYTES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MONITORING, IMMUNOLOGIC; PROGNOSIS; PROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS; VIRAL LOAD; VIRUS ACTIVATION;

EID: 84885399764     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074744     Document Type: Article

References (25)

1. Crough T, Khanna R, (2009) Immunobiology of human cytomegalovirus: from bench to bedside. Clin Microbiol Rev 22: 76-98.
2. Gandhi MK, Khanna R, (2004) Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis 4: 725-738.
3. Boeckh M, Nichols WG, (2004) The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 103: 2003-2008.
4. Boeckh M, Nichols WG, Papanicolaou G, Rubin R, Wingard JR, et al. (2003) Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies. Biol Blood Marrow Transplant 9: 543-558.
5. Lilleri D, Fornara C, Chiesa A, Caldera D, Alessandrino EP, et al. (2008) Human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection. Haematologica 93: 248-256.
6. Lilleri D, Gerna G, Fornara C, Lozza L, Maccario R, et al. (2006) Prospective simultaneous quantification of human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in young recipients of allogeneic hematopoietic stem cell transplants. Blood 108: 1406-1412.
7. Solano C, Benet I, Remigia MJ, de la Camara R, Munoz-Cobo B, et al. (2011) Immunological monitoring for guidance of preemptive antiviral therapy for active cytomegalovirus infection in allogeneic stem-cell transplant recipients: a pilot experience. Transplantation 92: e17-20.
8. Lamba R, Carrum G, Myers GD, Bollard CM, Krance RA, et al. (2005) Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with Alemtuzumab. Bone Marrow Transplant 36: 797-802.
9. Moins-Teisserenc H, Busson M, Scieux C, Bajzik V, Cayuela JM, et al. (2008) Patterns of cytomegalovirus reactivation are associated with distinct evolutive profiles of immune reconstitution after allogeneic hematopoietic stem cell transplantation. J Infect Dis 198: 818-826.
10. Borchers S, Luther S, Lips U, Hahn N, Kontsendorn J, et al. (2011) Tetramer monitoring to assess risk factors for recurrent cytomegalovirus reactivation and reconstitution of antiviral immunity post allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 13: 222-236.
11. Gratama JW, Boeckh M, Nakamura R, Cornelissen JJ, Brooimans RA, et al. (2010) Immune monitoring with iTAg MHC Tetramers for prediction of recurrent or persistent cytomegalovirus infection or disease in allogeneic hematopoietic stem cell transplant recipients: a prospective multicenter study. Blood 116: 1655-1662.
12. Avetisyan G, Aschan J, Hagglund H, Ringden O, Ljungman P, (2007) Evaluation of intervention strategy based on CMV-specific immune responses after allogeneic SCT. Bone Marrow Transplant 40: 865-869.
13. Lilleri D, Zelini P, Fornara C, Comolli G, Revello MG, et al. (2009) Human cytomegalovirus-specific CD4+ and CD8+ T cell responses in primary infection of the immunocompetent and the immunocompromised host. Clin Immunol 131: 395-403.
14. Lilleri D, Gerna G, Zelini P, Chiesa A, Rognoni V, et al. (2012) Monitoring of human cytomegalovirus and virus-specific T-cell response in young patients receiving allogeneic hematopoietic stem cell transplantation. PLoS One 7: e41648.
15. Walker S, Fazou C, Crough T, Holdsworth R, Kiely P, et al. (2007) Ex vivo monitoring of human cytomegalovirus-specific CD8+ T-cell responses using QuantiFERON-CMV. Transpl Infect Dis 9: 165-170.
16. Mazurek GH, LoBue PA, Daley CL, Bernardo J, Lardizabal AA, et al. (2001) Comparison of a whole-blood interferon gamma assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection. JAMA 286: 1740-1747.
17. Fleming T, Dunne J, Crowley B, (2010) Ex vivo monitoring of human cytomegalovirus-specific CD8(+) T-Cell responses using the QuantiFERON-CMV assay in allogeneic hematopoietic stem cell transplant recipients attending an Irish hospital. J Med Virol 82: 433-440.
18. Giulieri S, Manuel O, (2011) QuantiFERON(R)-CMV assay for the assessment of cytomegalovirus cell-mediated immunity. Expert Rev Mol Diagn 11: 17-25.
19. Kumar D, Chernenko S, Moussa G, Cobos I, Manuel O, et al. (2009) Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am J Transplant 9: 1214-1222.
20. Lisboa LF, Kumar D, Wilson LE, Humar A, (2012) Clinical utility of cytomegalovirus cell-mediated immunity in transplant recipients with cytomegalovirus viremia. Transplantation 93: 195-200.
21. Lochmanova A, Lochman I, Tomaskova H, Marsalkova P, Raszka J, et al. (2010) Quantiferon-CMV test in prediction of cytomegalovirus infection after kidney transplantation. Transplant Proc 42: 3574-3577.
22. Murphy E, Shenk T, (2008) Human cytomegalovirus genome. Curr Top Microbiol Immunol 325: 1-19.
23. Gratama JW, Brooimans RA, van der Holt B, Sintnicolaas K, van Doornum G, et al. (2008) Monitoring cytomegalovirus IE-1 and pp65-specific CD4+ and CD8+ T-cell responses after allogeneic stem cell transplantation may identify patients at risk for recurrent CMV reactivations. Cytometry B Clin Cytom 74: 211-220.
24. Feuchtinger T, Opherk K, Bethge WA, Topp MS, Schuster FR, et al. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood 116: 4360-4367.
25. Cantoni N, Hirsch HH, Khanna N, Gerull S, Buser A, et al. (2010) Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease. Biol Blood Marrow Transplant 16: 1309-1314.